BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology ...
U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma, by Bristol ...
Arcus Biosciences (RCUS) stock falls as the company and partner Gilead (GILD) halt a Phase 3 cancer trial evaluating its anti ...
US pharma major Bristol Myers Squibb has announced progress for its multi-indication cancer drug Opdivo (nivolumab) in ...
Based on phase 3 trial data, the FDA accepted an sBLA for nivolumab plus AVD for untreated stage III or IV classical Hodgkin lymphoma.
Bristol Myers Squibb Canada (BMS) is pleased to announce that OPDIVO® SC (nivolumab for subcutaneous injection) is now included on the Liste des Médicaments-Établissements. Quebec is the first ...
US FDA Grants Priority Review to Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy Combination for Classic Hodgkin Lymphoma ...
The Center Origin, a Colorado licensed Natural Medicine Healing Center, announced the continuance of its ongoing free wellness program designed exclusively for first responders and veterans. After ...
Diakonos Oncology has received more than $7 million from the Cancer Prevention and Research Institute of Texas to support a ...
The immunotherapies used to treat melanoma now include well-established drugs such as Keytruda (pembrolizumab) and Opdivo (nivolumab) and newer ones such as Amtagvi (lifileucel), which uses T cells ...
A modified immunotherapy regimen for advanced melanoma showed a 49% response rate and extended median overall survival to 42 ...
The global Merkel Cell Carcinoma (MCC) market is rapidly evolving, driven by advancements in immunotherapy and a surge in early diagnoses. Merkel cell carcinoma, a rare, aggressive skin cancer mainly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback